Fibrous encapsulation of defibrillation electrode and elevated high-voltage impedance in patients with a subcutaneous implantable cardioverter-defibrillator

Jian-Ming Li, MD, PhD, FHRS,* † Yanhui Li, MD, PhD,‡ Venkatakrishna Tholakanahalli, MD, FHRS, * † David G. Benditt, MD, FHRS* †

From the *Division of Cardiology, Veterans Affairs Medical Center, Minneapolis, Minnesota, †Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesota, and ‡First Hospital of Tsinghua University, Tsinghua University, Beijing, China.

Introduction
The use of conventional transvenous implantable cardioverter-defibrillators (ICDs) is well established for prevention of sudden cardiac death (SCD) from ventricular tachyarrhythmias.1,2 However, venous lead failure, venous thrombosis, and infections may complicate follow-up.3 An entirely subcutaneous ICD (S-ICD) is an option for some patients at SCD risk, whenever there is a desire to avoid transvenous leads or prior transvenous system complications have occurred. The safety and effectiveness of S-ICDs have been demonstrated both in clinical trials and in noncontrolled registration studies; however, such systems are not immune from adverse events.5–8 Herein, we report 2 cases of fibrous encapsulation of the S-ICD defibrillation shock electrode at 2 years after implantation and its potential impact on the high-voltage impedance and defibrillation test (DT).

Case report
Case #1
A 61-year-old man with ischemic cardiomyopathy was referred for S-ICD implantation for primary SCD prevention. Past cardiac history included ST-elevation acute myocardial infarction with primary angioplasty and stenting of the left circumflex coronary artery (Promus DES; Boston Scientific Inc, St Paul, MN) and left ventricular dysfunction (ejection fraction 30%) under optimized medical therapy. Other medical history included type 2 diabetes mellitus, chronic kidney disease stage 3, hypertension, chronic obstructive pulmonary disease, stage 1 lung adenocarcinoma with expected life expectancy >1 year, and obesity with body mass index (BMI) of 34. S-ICD implantation was performed according to the standard protocol, but with the 2-incision technique. The pulse generator (EMBLEM S-ICD, model A209; Boston Scientific Inc, St Paul, MN) and the lead (Q-TRAK SQ 3400; Boston Scientific Inc, St Paul, MN) were used. DT was deferred owing to the presence of a left ventricular apical thrombus. At 2 years post implantation, DT failed with 65 J and 70 J shock on 2 separate ventricular fibrillation (VF) inductions, with high-voltage lead impedances (HVLI) of 153 ohms and 138 ohms, respectively. On both occasions, 200 J biphasic shocks with an external defibrillator were used successfully in terminating VF. Consequently, system revision was undertaken.

At the time of lead revision, there was a dense fibrous tissue encapsulating the shock electrode. Histological findings of cross-section specimens showed connective tissue with collagen fiber arranged in parallel without inflammatory cells (Figure 1). We manually peeled away the fibrous tissue from the lead. The original lead was repositioned slightly toward the right side of the sternum. DT was successful with 65 J...
with a high-voltage impedance of 85 ohms. During follow-up of 2.5 years since implant, there has been no S-ICD therapy for ventricular arrhythmia. The patient died 6 months after S-ICD generator revision from unknown cause.

Case #2
A 58-year-old man with noncompaction cardiomyopathy and left ventricular ejection fraction of 30%–35% received an S-ICD for primary SCD prevention. Past medical history included obstructive sleep apnea and nonischemic dilated cardiomyopathy with BMI of 31. S-ICD implantation was performed according to the standard protocol with the 2-incision technique. The pulse generator (EMBLEM S-ICD, model A209; Boston Scientific Inc, St Paul, MN) and the lead (Q-TRAK SQ 3401; Boston Scientific Inc, St Paul, MN) were used. A successful DT was performed with 65 J shock and HVLI of 98 ohms at implant. Owing to the concerns of S-ICD lead fibrosis and its potential impact on DT as observed in case 1, we performed DT at the 2-year follow-up. The HVLI was 185 ohms with a 10 J shock from S-ICD. VF was then induced with 50 Hz pacing; however, VF was under-sensed by the device (Figure 2, top left). A 65 J shock with HVLI of 170 ohms from the S-ICD was manually delivered, without success. He was successfully rescued with an external defibrillator at 200 J biphasic shock.

During lead revision, the shock electrode was removed by the simple traction technique and a dense fibrous capsule over the shock electrode was observed, similar to that seen in case 1. Before we removed the shock electrode, a long suture was attached to the suture ring at the distal end of the electrode. When the electrode was pulled out, the suture attached to the lead tip remained in the subcutaneous tunnel with its free end secured outside the wound (Figure 2, top right). After the removal of the fibrous capsule, we could easily reposition the electrode back along the same track by pulling on the suture up along the sternum (Figure 2, bottom). The S-ICD wound was closed. There was no blood or saline injection to the subcutaneous tunnel during this lead revision. A successful DT was performed at 65 J shock with HVLI of
77 ohms. During his 1-year follow-up after lead revision, a successful DT was performed with stable HVLI of 87 ohms and 79 ohms at 65 J, respectively. HVLIs measured directly by high-voltage shock for both patients at initial S-ICD implant and before, during, and after S-ICD system revision are summarized in Table 1.

**Discussion**

We observed dense fibrous encapsulation of defibrillation electrodes in 2 patients with S-ICD after 2 years post system implantation. High HVLIs were seen in both patients with failed DT. Removal of fibrous tissues encapsulating the electrodes with minimal or no changes of S-ICD generator and pocket was performed. We conclude that fibrous encapsulation is an event that can happen in S-ICD patients and can be managed with revision of fibrous tissues with minimal changes of the S-ICD system.

### Table 1

| Clinical characteristics and high-voltage lead impedance measured by high-voltage shock at initial implant and before, during, and after subcutaneous implantable cardioverter-defibrillator system revision |
|---|---|---|
| **Case 1** | **Case 2** |  |
| **Age** | 61 | 58 |
| **Sex** | Male | Male |
| **Indication** | Primary prevention | Primary prevention |
| **BMI** | 34 | 31 |
| **LVEF** | 30% | 30% |
| **LV thickness (septum/posterior wall)** | 1.2 cm/1.2 cm | 1.1 cm/1.1 cm |
| **Renal function (GFR, mL/min/1.73 m²)** | 34 | >60 |
| **DT at initial implant** | Not done |  |
| **Failed DT at 2 years after implant** | 153 ohms @65J | 98 ohms @ 65 J |
| | 138 ohms@70J | 185 ohms @ 10 J |
| **Revision with successful DT** | 85 ohms @65J | 170 ohms @ 65 J |
| **Pocket revision** | No | No |
| **Follow-up after revision** | Died of unknown cause at 6 months | Successful DT at 1 year |
| | | 87 ohms @ 65 J |
| | | 79 ohms @ 65 J |

*BMI = body mass index; DT = defibrillation test; GFR = glomerular filtration rate; ICM = ischemic cardiomyopathy; LV = left ventricle; LVEF = left ventricular ejection fraction; NICM = nonischemic cardiomyopathy.*
shock electrode position resulted in marked reduction of HVLIs and successful DT. We proposed here that fibrous tissue formation around the defibrillation electrode in some individual patients may cause HVLI elevation and potentially affect S-ICD performance.

Collagen as a biological insulator under physiological conditions has been previously reported. Dense layers of collagen tissues observed in our 2 patients might have resulted in shock energy being wasted, thereby increasing DT. Significant HVLI changes were reported in 41% of transvenous ICD shock electrodes after 3 months of implantation, with changes >12 ohms and >50 ohms in 8% and 0.4% patients, respectively. While factors such as lead orientation, recoiling, and lead contact to myocardium were responsible for HVLI changes in the acute phase, fibrous tissue formation over shock electrodes was considered the main reason for HVLI changes in the weeks and months after implant. HVLI changes of 6–12 ohms could alter the characteristics of the shock waveform, responsible for the 15% increase in DT over time.

No previous studies have examined the impact of fibrous tissue formation on the HVLI in an S-ICD system. The pacing pulse test for calculating shock lead impedance was used for transvenous ICD systems to monitor HVLI changes over time. The test consists of a 4 V positive pulse (20 μs) between the electrode and the can and then a second pulse at 4 V in the opposing polarity. However, this method has not been systematically validated for the S-ICD system. Based on the characteristics of the electric circuit and the calibration constant during manufacturing, engineers formulated a best-fit quadratic equation to improve the accuracy of calculating impedance measurements (personal communication). The HVLI weekly recordings from these 2 patients were downloaded from the S-ICD system; the highest monthly impedances are shown in Figure 3. There was no difference in overall trends when we compared the trend of using the highest monthly impedance and using the weekly impedance. The trends of HVLI changes from both patients appeared to share the following common characteristics. First, there was an initial rise of impedance, which peaked around 3 months after implant. Second, there was a plateau phase from 3 months to 18–20 months. This was followed by a second impedance rise before they peaked at 22–24 months. Third, after lead revision with removal of fibrous tissue, the impedance remained stable at 4–8 months after revision. The mechanisms of early (3 months) and late (22–24 months) HVLI increases remain unknown. Previous animal studies for other biocompatible materials implanted subcutaneously indicated that total fibrous encapsulation occurred by 90 days after implant. Of note, there was an excellent correlation between the impedance calculated by the pacing pulse method and HVLI directly measured by 65 J shock around the time of DT. Long-term follow-up is needed to determine if significant HVLI changes occur later in device life.

Factors influencing DT in patients with S-ICD have not been well studied. In a retrospective study, high S-ICD DT were associated with increased BMI, body surface area, and septal or posterior wall thickness. A high-voltage impedance of >138 ohms appeared to predict patients with high DTs in a univariate analysis. In our cases, failed DTs were observed with HVLI of 138 ohms and 170 ohms, respectively. In a computer modeling study on the determinants of S-ICD efficacy, addition of sub-coil and sub-generator fat increased shock impedance. Calculated DT were increased 3-fold with the addition of 10 mm sub-coil fat. Fibrous encapsulation of the shock electrodes seen in our

![Figure 3](image.png)  
**Figure 3**  
Trends of high-voltage impedance measured by low-voltage pacing pulse during 25 months of follow-up. Arrow indicates the high-voltage impedance with 65 J shock at the time of failed defibrillation test.
cases may function as a “biological insulator” just like the sub-coil fat, to increase the shock impedance and DT. In case 2, we showed marked decrease of HVLI impedance to the baseline level after the removal of the fibrous encapsulation and repositioning of the shock electrode to the same location. This suggests that the fibrous encapsulation was responsible for most of the HVLI rise after implant for this patient. Owing to the subcutaneous location of the shock electrode, there is minimal blood or body fluid pooling from the lead extraction to account for the impedance decrease. Nevertheless, the probabilistic nature of defibrillation added to the complexity and difficulties in determining the true effect of the fibrous encapsulation on the defibrillation threshold.

Limitations
We could not draw any conclusion about whether the finding from these 2 cases is common to other shock leads. A prospective registry on lead impedance over time will help to confirm if this observation is clinically significant in a large population of S-ICD implants.

Conclusion
In conclusion, we showed here that fibrous encapsulation of the S-ICD defibrillation shock electrode occurred in 2 patients after S-ICD implant, which caused both an elevated high-voltage impedance and failed DT. Further studies are needed to determine the frequency with which this phenomenon occurs and whether fibrous encapsulation may adversely affect long-term performance of S-ICD defibrillation systems.

References
1. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
2. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.
3. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of 10 years. Circulation 2007;115:2474–2480.
4. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter–defibrillator. N Engl J Med 2010;363:36–44.
5. Boersma L, Barr C, Knops R, et al; EFFORTLESS Investigator Group. Implant and midterm outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol 2017; 70:830–841.
6. Chue CD, Kwok CS, Wong CW, et al. Efficacy and safety of the subcutaneous implantable cardioverter defibrillator: a systematic review. Heart 2017; 103:1315–1322.
7. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable cardioverter defibrillator. Circulation 2013;128:944–953.
8. Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter defibrillators: a multicenter case-control study. Heart Rhythm 2013;10:29–36.
9. Tzukert A, Leviner E, Mahler Y, Shoshan S. Electroconductivity of collagen in vitro and in vivo. Biochim Biophys Acta 1980;627:276–280.
10. Val-Mejias JE, Janet DR, Ramadas S. Long-term changes in high-voltage impedance of defibrillating leads. Pacing Clin Electrophysiol 2009;32(Suppl 1):S151–S154.
11. Mehdirad AA, Stohr EC, Love CJ, Nelson SD, Schaal SF. Implantable defibrillators impedance measurement using pacing pulses versus shock delivery with intact and modified high voltage lead system. Pacing Clin Electrophysiol 1999; 22:437–441.
12. Butler K, Benghuzzi H, Tucci S. Tissue-implant response following soft tissue implantation of poly-L-lysine coated UHMW-polyethylene into adult male rats. Biomed Sci Instrum 2001;37:19–24.
13. Konecny T, Carlson SK, Tun H, Huntsinger M, Doshi RN. Predictors of elevated defibrillation threshold with the subcutaneous implantable cardioverter-defibrillator. The Journal of Innovations in Cardiac Rhythm Management 2017; 8:2920–2929.
14. Heist K, Belalcazar A, Stahl AW, Brouwer TF, Knops RE. Determinants of subcutaneous implantable cardioverter-defibrillator efficacy: a computer modeling study. JACC Clin Electrophysiol 2017;3:405.